Samsung Medison Co. said on the 9th it will pursue a strategic collaboration with the U.S. corporations HistoSonics, which has noninvasive, ultrasound-based cancer treatment technology.
The two companies will work to link in real time Samsung Medison Co.'s premium ultrasound diagnostic device R20 with HistoSonics' therapeutic equipment, the Edison system. They plan to stably transmit high-resolution ultrasound images obtained from the R20 to the Edison system and, reflecting the high-intensity acoustic environment that occurs during treatment, to redesign both the image signal processing architecture and the system interface.
The linked Edison system selectively destroys tumor tissue using a "histotripsy" method that precisely focuses ultrasound on the tumor area to create microbubbles and then collapses them. Because the procedure is noninvasive and does not require an incision, it can reduce patients' recovery burden, and based on real-time imaging, it can improve procedural accuracy and safety by confirming the treatment area.
The two companies plan to pioneer new markets by combining Samsung Medison Co.'s precision diagnostic imaging technology with HistoSonics' therapeutic technology and to strengthen competitiveness in the field of ultrasound-based treatment.
Yu Gyu-tae, head of Samsung Medison Co., said, "This collaboration is an important turning point that connects diagnosis and treatment based on the scalability of ultrasound technology," and added, "We will expand strategic partnerships with promising global corporations to diversify our business portfolio and secure future growth engines."